TY - JOUR
T1 - Quickest Way to Less Headache Days: an operational research model and its implementation for Chronic Migraine
JF - medRxiv
DO - 10.1101/2022.03.29.22273147
SP - 2022.03.29.22273147
AU - Irene Lo
AU - Pengfei Zhang
Y1 - 2022/01/01
UR - http://medrxiv.org/content/early/2022/04/01/2022.03.29.22273147.abstract
N2 - Background Choosing migraine prevention medications often involves trial and error. Operations research methodologies, however, allow us to derive a mathematically optimum way to conduct such trial and error processes.Objective Given probability of success (defined as 50% reduction in headache days) and adverse events as a function of time, we seek to develop and solve an operations research model, applicable to any arbitrary patient, minimizing time until discovery of an effective migraine prevention medication. We then seek to apply our model to real life data for chronic migraine prevention.Methods We develop a model as follows: Given a set of D many preventive medications, for drug i in D, we describe the likelihood of reaching 50% headache day reduction over the course of time, (ti,1 ≤ ti,2 ≤ …) by probability (pi,1 ≤ pi,2 ≤ …). We additionally assume a probability of adverse event(qi,1 ≤ qi,2 ≤ …). We then solve for a sequence of prescription trials that minimizes the expected time until an effective drug is identified.Once we identify the optimal sequence for our model, we estimate p, t and q for topiramate and OnabotulinumtoxinA based on the FORWARD study by Rothrock et al as well as erenumab data published by Barbanti et al. at IHC 2019.Results The solution for our model is to order the drugs by probability of efficacy per unit time. When the efficacy of each drug i is known only for one period ti and there are no adverse effects, then the optimum sequence is to administer drug i for ti periods in decreasing order pi/ti. In general, the optimum sequence is to administer drug i for ti,k* periods in decreasing order of the Gittins index σi,k*Based on the above data, the optimum sequence of chronic migraine prevention medication is a trial of erenumab for 12 weeks, followed by a trial of OnabotulinumtoxinA for 32 weeks, followed by a trial of topiramate for 32 weeks.Conclusion We propose an optimal sequence for preventive medication trial for patients with chronic migraine. Since our model makes limited assumptions on the characteristics of disease, it can be readily applied also to episodic migraine, given the appropriate data as input.Indeed, our model can be applied to other scenarios so long as probability of success/adverse event as a function of time can be estimated. As such, we believe our model may have implications beyond our sub-specialty.Trial Registration Not applicable.Competing Interest StatementIrene Lo: No conflict Pengfei Zhang: He has received honorarium from Alder Biopharmaceuticals, Board Vitals, Fieve Clinical Research. He collaborates with Headache Science Incorporated without receiving financial support. He has ownership interest in Cymbeline LLC. Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors(IHC)International Headache Congress(OR)Operations Research(HIV)Human Immunodeficiency Virus(MDP)Markov Decision Process(CGRP)calcitonin gene-related peptid
ER -